First UK centre joins Invivo Therapeutics’ INSPIRE study

50
Invivo Therapeutics’ Neuro-spinal scaffold

James Cook University Hospital in Middlesbrough, UK,  has been added as the country’s first clinical site for Invivo Therapeutics’ INSPIRE study (InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold for Safety and Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury).

The Golden Jubilee Regional Spinal Cord Injuries Centre located at the James Cook University Hospital, a major trauma centre, focuses exclusively on patients with spinal cord injuries, and is one of eight specialist centres within England.

“I am enthusiastic about the opportunity to be joining the INSPIRE study, and I look forward to helping InVivo evaluate this exciting experimental technology while bringing awareness of the study to the UK,” says Manjunath Prasad, a spinal cord researcher based at the new site.

Stanford Medicine in Stanford, USA is also joining the INSPIRE study. Atman Desai, has been named principal investigator at the site. Desai is a director of Neurosurgical Spinal Oncology and clinical assistant professor of Neurosurgery at Stanford University Medical Center.

There are now 34 clinical sites participating in the clinical study across the USA, Canada, and now the UK:

  • Allegheny General Hospital, Pittsburgh, USA
  • Banner University Medical Center, Tucson, USA
  • Barnes-Jewish Hospital at Washington University Medical Center, St Louis, USA
  • Barrow Neurological Institute – St. Joseph’s Hospital and Medical Center, Phoenix, USA
  • Ben Taub Hospital/Baylor College of Medicine, Houston, USA
  • Beth Israel Deaconess Medical Center, Boston, USA
  • Brigham and Women’s Hospital, Boston, USA
  • Carolina Neurosurgery and Spine Associates/Carolinas Rehabilitation, Charlotte, USA
  • Cooper Neurological Institute, Camden, USA
  • Foothills Medical Centre, Calgary, Canada
  • Goodman Campbell Brain and Spine/Indiana University Health Neuroscience Center, Indianapolis, USA
  • Hospital of the University of Pennsylvania, Philadelphia, USA
  • James Cook University Hospital, Middlesbrough, UK
  • Keck Hospital of University of Southern California, Los Angeles, USA
  • Medical College of Wisconsin/Froedtert Hospital, Milwaukee, USA
  • Mount Sinai Hospital, New York, USA
  • Northwestern Medicine, Chicago, USA
  • Oregon Health & Science University, Portland, USA
  • Rhode Island Hospital, Providence, USA
  • Rutgers New Jersey Medical School, Newark, USA
  • Stanford Medicine, Stanford, USA
  • Michael’s Hospital, Toronto, Canada
  • Thomas Jefferson University Hospital, Philadelphia, USA
  • Toronto Western Hospital, Toronto, ON, Canada
  • UC Health Memorial Hospital, Colorado Springs, USA
  • University of California, Davis Medical Center, Sacramento, USA
  • University of California, San Diego Medical Center, San Diego, USA
  • University of Iowa Hospitals and Clinics, Iowa City, USA
  • University of Kansas Medical Center, Kansas City, USA
  • University of Louisville Hospital, Louisville, USA
  • University of New Mexico Hospital, Albuquerque, USA
  • University of Pittsburgh Medical Center Presbyterian, Pittsburgh, USA
  • University of Virginia Health System, Charlottesville, USA
  • Vidant Medical Center, Greenville, USA

Invivo Therapeutics has also announced that Richard Toselli will join Invivo Therapeutics as chief medical officer. Toselli, a fellowship-trained spinal neurosurgeon, will assume all responsibilities related to the company’s clinical and regulatory strategy.

Prior to joining InVivo, Toselli served as chief medical officer for Cochlear Limited. Prior to this position, Toselli served five years at Sanofi in various levels of increasing responsibility, including vice president of Global Medical Affairs – Immunology and Inflammation, Biologics Division; vice president of Global Medical Affairs and head of the Biosurgery Discovery Performance Unit; and vice president of Global Medical Affairs, Biosurgery. Before his time at Sanofi, he served as chief medical/technology officer for Covidien Surgical, and earlier held various roles at DePuy Spine including director of Medical Affairs, Worldwide Vice President of Research and Development, and worldwide vice president of Clinical Evidence and External Relations. He subsequently held the position of vice president of Evidence-Based Medicine at Johnson & Johnson for the device sector.

Toselli’s previous academic positions include assistant professor at Brown University (Providence, USA), associate professor, director of Spine Center, and associate chief of Staff at the University of North Carolina (UNC, Chapel Hill, USA), and associate professor at the University of Vermont (Burlington, USA). He holds a bachelor of arts from Providence College (Providence, USA), his medical degree from Brown University, and a masters of business administration from the UNC’s Kenan-Flagler Business School. Toselli is a board-certified neurological surgeon.

LEAVE A REPLY